Why Is CAREDX INC (CDNA) Stock Moving Today?

Why CDNA stock is up today

CareDx Inc. (CDNA) surged 35.60% to $40.34 in the latest session, driven by the finalization of Medicare coverage for its molecular transplant surveillance tests. The policy change, which grants reimbursement for kidney, heart, and lung transplant monitoring, has bolstered investor confidence and triggered a sharp rally in the stock. The move comes after a period of volatility and sets the stage for broader adoption of CareDx's services.

What Happened

The stock’s sharp rise follows the confirmation of a finalized Medicare Local Coverage Determination (LCD) for CareDx’s molecular testing. This policy shift ensures coverage for up to six tests in the first year and four annually in the following two years for kidney rejection surveillance. The final policy is expected to take effect on August 30. The news has been interpreted as a key validation of CareDx’s market position and a catalyst for future revenue growth. The stock had already seen an 18% jump earlier in the session, with the day’s move marking a significant reversal from recent underperformance.

What The Data Shows

The stock’s 52-week range is $10.96 to $30.00, meaning the current price is well above its previous high. The session’s volume was unusually high, though specific figures were not provided. Recent insider transactions show six sales totaling $2.7 million over the last 90 days, with no insider purchases recorded. Despite the stock’s strong performance, CareDx remains unprofitable, with a trailing twelve-month net margin of -2.0% and an EPS of -0.16. The company’s revenue has grown 19.2% in the same period.

What To Watch

Investors will now look to CareDx’s second quarter 2026 financial results, scheduled for release on July 30. The earnings report will be followed by a webcast and conference call, offering further insight into the company’s financial health and the potential impact of the new Medicare coverage.